Westfield Capital Management Co. LP Has $66.21 Million Position in Haemonetics Co. (NYSE:HAE)

Westfield Capital Management Co. LP raised its holdings in shares of Haemonetics Co. (NYSE:HAE) by 10.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 823,663 shares of the medical instruments supplier’s stock after purchasing an additional 80,783 shares during the quarter. Westfield Capital Management Co. LP owned approximately 1.61% of Haemonetics worth $66,206,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Silvercrest Asset Management Group LLC acquired a new stake in shares of Haemonetics during the 1st quarter worth about $38,706,000. Price T Rowe Associates Inc. MD lifted its position in Haemonetics by 38.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after acquiring an additional 156,665 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Haemonetics by 311.4% during the second quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock worth $2,132,000 after acquiring an additional 19,510 shares during the period. Global Alpha Capital Management Ltd. acquired a new position in shares of Haemonetics in the third quarter valued at approximately $806,000. Finally, Janus Henderson Group PLC increased its stake in shares of Haemonetics by 26.8% during the first quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock worth $2,536,000 after purchasing an additional 6,287 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Up 0.1 %

Shares of HAE opened at $85.55 on Friday. The firm has a 50 day simple moving average of $78.75 and a two-hundred day simple moving average of $82.40. The company has a market cap of $4.30 billion, a P/E ratio of 35.50, a P/E/G ratio of 1.33 and a beta of 0.32. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.99 EPS. Research analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HAE. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a report on Friday, November 8th. BTIG Research started coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research report on Friday, November 15th. Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research report on Friday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and an average target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.